Literature DB >> 30137546

Delay before drug susceptibility testing among patients with presumptive multidrug-resistant tuberculosis in Gujarat, India.

Hemant Deepak Shewade1, Kalpita S Shringarpure2, Malik Parmar3, Nikhil Patel2, Suraj Kuriya2, Samarth Shihora2, Nittal Ninama2, Narendra Gosai2, Rahul Khokhariya2, Chetan Popat2, Hiren Thanki3, Bhavesh Modi4, Paresh Dave5, R K Baxi2, Ajay M V Kumar1,6.   

Abstract

Background: Reducing delay in the diagnosis of multidrug-resistant tuberculosis (MDR-TB) by performing genotypic drug susceptibility testing (DST) among eligible patients as early as possible can improve clinical presentation and treatment outcomes and reduce transmission. We aimed to determine the delay from being eligible for DST to performing DST and factors associated with the delay.
Methods: This was a retrospective cohort study involving record review among presumptive MDR-TB patients who underwent genotypic DST from five selected districts in the state of Gujarat, India (2014). Specimens were couriered from the designated microscopy centres (DMCs) to two designated genotypic DST facilities located outside the districts.
Results: Of 2212 patients, the median duration from eligibility to the specimen being sent, from the specimen being sent to DST and from eligibility to DST was 3, 5 and 8 d, respectively. Patients from DMCs in teaching hospitals and with presumptive MDR-TB criteria 'follow-up smear positive' and 'TB-human immunodeficiency virus co-infection' had a significantly higher risk of delay between eligibility and testing (≥8 d). The delay in the specimen being sent after eligibility contributed to high delays in these subgroups.
Conclusion: The districts were doing well in implementing timely DST among presumptive MDR-TB patients. However, there is room for improvement in reducing the delays in the sending of specimens among certain patient subgroups.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30137546     DOI: 10.1093/trstmh/try091

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  2 in total

1.  Evaluation of Xpert MTB-RIF guided diagnosis and treatment of rifampicin-resistant tuberculosis in Indonesia: A retrospective cohort study.

Authors:  Arto Yuwono Soeroto; Bony Wiem Lestari; Prayudi Santoso; Lidya Chaidir; Basti Andriyoko; Bachti Alisjahbana; Reinout van Crevel; Philip C Hill
Journal:  PLoS One       Date:  2019-02-28       Impact factor: 3.240

2.  Assessing the impacts of short-course multidrug-resistant tuberculosis treatment in the Southeast Asia Region using a mathematical modeling approach.

Authors:  Win Min Han; Wiriya Mahikul; Thomas Pouplin; Saranath Lawpoolsri; Lisa J White; Wirichada Pan-Ngum
Journal:  PLoS One       Date:  2021-03-26       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.